Peter Nicol

8.3k citations
24 papers · 6.3k · 6 hit papers · h-index 16

Impact in

    • Venous Thromboembolism Diagnosis and Management
    • Diabetes Treatment and Management
    • Hyperglycemia and glycemic control in critically ill and hospitalized patients
    • Diabetes, Cardiovascular Risks, and Lipoproteins
    • Diabetes Management and Research

Papers in

Peter Nicol

24 papers receiving 5.8k citations

Peter Nicol's Hit Papers

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES 2025 · 19 citations
190+10+20Years since publication5001k1.5k2k

Peers

Peter Nicol
Comparison fields: 5 of 93
  • Internal Medicine 1.5k
  • Endocrinology, Diabetes and Metabolism 3k
  • Nephrology 429
  • Cardiology and Cardiovascular Medicine 792
  • Surgery 639
Replace URSZULA S. MASIUKIEWICZ with:
URSZULA S. MASIUKIEWICZ United States
Carlos Alberto Cuneo Canada
Oscar Gómez Vilamajó Canada
Mauro Esteves Hernandes Brazil
Cesar Javier Zaidman United Kingdom
Thomas Mooe Sweden
Carlos Jerjes-Sánchez D Mexico
Katalin Keltai Hungary
Eve Gillespie United Kingdom
Euler Roberto Fernandes Manenti Brazil
Peter Nicol relative to URSZULA S. MASIUKIEWICZ United States URSZULA S. MASIUKIEWICZ's profile →
Citations per field
00.5×1.5×2.2×
URSZULA S. MASIUKIEWICZ · 1×
Citations per year

Countries citing papers authored by Peter Nicol

Since Specialization
Citations

This map shows the geographic impact of Peter Nicol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Nicol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Nicol more than expected).

Fields of papers citing papers by Peter Nicol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Nicol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Nicol. The network helps show where Peter Nicol may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Nicol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Nicol Line = papers co-authored together Peter Nicol links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hit paper breakdown →
20192345
2
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year
Hit paper breakdown →
19951202
3
A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
Hit paper breakdown →
1995752
4
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hit paper breakdown →
2019498
5 1997471
6 2006409
7
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Hit paper breakdown →
2019244
8 2021116
9 202278
10 199639
11 197633
12
Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy.
199430
13 202128
14 199523
15
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Hit paper breakdown →
202519
16 199417
17 202415
18
Evaluation of myocardial infarct size before and after reperfusion: dual-tracer imaging with radiolabeled antimyosin antibody.
19948
19
Synthetic peptide immunogens for the development of a cardiac myosin light chain-1 specific radioimmunoassay.
19936
20 19913

About Peter Nicol

Peter Nicol is a scholar working on Internal Medicine, Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Surgery and Nephrology, having authored 24 papers that have together received 6.3k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (6 papers), Venous Thromboembolism Diagnosis and Management (4 papers), Viral Infections and Immunology Research (3 papers), Acute Myocardial Infarction Research (3 papers), Cardiac Imaging and Diagnostics (2 papers), Diabetes Treatment and Management (2 papers), Medical History and Innovations (1 paper) and Healthcare Systems and Public Health (1 paper). The work is most often cited by research in Internal Medicine (1.5k citations), Endocrinology, Diabetes and Metabolism (3k citations), Nephrology (429 citations), Cardiology and Cardiovascular Medicine (792 citations) and Surgery (639 citations). Peter Nicol has collaborated with scholars based in Sweden, United States and Canada. Frequent co-authors include Johan D. Herlitz, Lennart Welin, Klas Malmberg, Lars Rydén, Suad Efendić, Hans Wedel, Anders P. Waldenström, Per Lindmarker, Anders Carlsson and Sam Schulman. Their work appears in journals such as The Lancet, Circulation, European Heart Journal, Journal of the American College of Cardiology and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact